abiraterone

You have access
Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study
JIAN-RI LI, SHIAN-SHIANG WANG, CHUAN-SHU CHEN, CHENG-KUANG YANG, KEVIN LU, CHEN-LI CHENG, SHENG-CHUN HUNG, SHU-YEN CHEN, CHIANN YI HSU and KUN-YUAN CHIU

Anticancer Research October 2022, 42 (10) 4857-4866; DOI: https://doi.org/10.21873/anticanres.15991
Open Access
Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease
NAOHIRO FUJIMOTO, AKINORI MINATO, TSUKASA IGAWA, TASUKU HIROSHIGE, WATARU OBARA, ATSUSHI FUKUDA, YUJIRO NAGATA, YUI MIZUSHIMA, IKKO TOMISAKI and KENICHI HARADA

Anticancer Research June 2022, 42 (6) 3041-3047; DOI: https://doi.org/10.21873/anticanres.15790
You have access
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel
MASAKI SHIOTA, MOTONOBU NAKAMURA, AKIRA YOKOMIZO, TOSHIHISA TOMODA, NAOTAKA SAKAMOTO, NARIHITO SEKI, SHUJI HASEGAWA, TAKAKAZU YUNOKI, MASAHIKO HARANO, KENTARO KUROIWA and MASATOSHI ETO

Anticancer Research January 2020, 40 (1) 335-339; DOI: https://doi.org/10.21873/anticanres.13957
You have access
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
DANIEL J. BECKER, ARJUN D. IYENGAR, SALMAN R. PUNEKAR, JASON NG, ANIKA ZAMAN, STACY LOEB, KEVIN D. BECKER and DANIL MAKAROV

Anticancer Research May 2019, 39 (5) 2467-2473; DOI: https://doi.org/10.21873/anticanres.13366
You have access
Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy
BEATRICE DETTI, ROLANDO M. D'ANGELILLO, GIANLUCA INGROSSO, EMANUELA OLMETTO, GIULIO FRANCOLINI, LUCA TRIGGIANI, ALESSIO BRUNI, SIMONA BORGHESI, SIMONA FONDELLI, TOMMASO CARFAGNO, ROBERTO SANTINI, RICCARDO SANTONI, LUCA E. TRODELLA and LORENZO LIVI

Anticancer Research July 2017, 37 (7) 3717-3722;
You have access
What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
RHIAN SIÂN DAVIES, CHRISTIAN SMITH, MICHAEL ROBERT BUTTON, JACOB TANGUAY, JIM BARBER, NACHIAPPAN PALANIAPPAN, JOHN STAFFURTH and JASON FRANCIS LESTER

Anticancer Research October 2015, 35 (10) 5615-5621;
You have access
Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer
ROBERTO PETRIOLI, EDOARDO FRANCINI, ANNA IDA FIASCHI, LETIZIA LAERA, SALVATORA TINDARA MIANO, GIOVANNI DE RUBERTIS and GIANDOMENICO ROVIELLO

Anticancer Research May 2015, 35 (5) 3097-3102;
You have access
Predictive Factors for Response to Abiraterone in Metastatic Castration Refractory Prostate Cancer
MEHRAN AFSHAR, FAWAZ AL-ALLOOSH, SARAH PIRRIE, CLARE ROWAN, NICHOLAS D. JAMES and EMILIO PORFIRI

Anticancer Research February 2015, 35 (2) 1057-1063;
You have access
Resistance to Abiraterone in Castration-resistant Prostate Cancer: A Review of the Literature
SILVANA GIACINTI, MARIA BASSANELLI, ANNA MARIA ASCHELTER, ANNALISA MILANO, MICHELA ROBERTO and PAOLO MARCHETTI

Anticancer Research November 2014, 34 (11) 6265-6269;

Main menu

User menu

Search

abiraterone